620 related articles for article (PubMed ID: 32058845)
1. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.
Brown PD; Gondi V; Pugh S; Tome WA; Wefel JS; Armstrong TS; Bovi JA; Robinson C; Konski A; Khuntia D; Grosshans D; Benzinger TLS; Bruner D; Gilbert MR; Roberge D; Kundapur V; Devisetty K; Shah S; Usuki K; Anderson BM; Stea B; Yoon H; Li J; Laack NN; Kruser TJ; Chmura SJ; Shi W; Deshmukh S; Mehta MP; Kachnic LA;
J Clin Oncol; 2020 Apr; 38(10):1019-1029. PubMed ID: 32058845
[TBL] [Abstract][Full Text] [Related]
2. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001.
Gondi V; Deshmukh S; Brown PD; Wefel JS; Armstrong TS; Tome WA; Gilbert MR; Konski A; Robinson CG; Bovi JA; Benzinger TLS; Roberge D; Kundapur V; Kaufman I; Shah S; Usuki KY; Baschnagel AM; Mehta MP; Kachnic LA
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):571-580. PubMed ID: 37150264
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the heterogeneity of hippocampal avoidant whole brain radiotherapy treatment effect: A secondary analysis of NRG CC001.
Cherng HR; Sun K; Bentzen S; Armstrong TS; Gondi V; Brown PD; Mehta M; Mishra MV
Neuro Oncol; 2024 May; 26(5):911-921. PubMed ID: 38069666
[TBL] [Abstract][Full Text] [Related]
4. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.
Gondi V; Pugh SL; Tome WA; Caine C; Corn B; Kanner A; Rowley H; Kundapur V; DeNittis A; Greenspoon JN; Konski AA; Bauman GS; Shah S; Shi W; Wendland M; Kachnic L; Mehta MP
J Clin Oncol; 2014 Dec; 32(34):3810-6. PubMed ID: 25349290
[TBL] [Abstract][Full Text] [Related]
5. Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial.
Yang WC; Chen YF; Yang CC; Wu PF; Chan HM; Chen JL; Chen GY; Cheng JC; Kuo SH; Hsu FM
Neuro Oncol; 2021 Mar; 23(3):478-486. PubMed ID: 32789503
[TBL] [Abstract][Full Text] [Related]
6. Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance.
Martinage G; Hong AM; Fay M; Thachil T; Roos D; Williams N; Lo S; Fogarty G
Radiat Oncol; 2018 Jul; 13(1):132. PubMed ID: 30029684
[TBL] [Abstract][Full Text] [Related]
7. Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol.
Chia BSH; Leong JY; Ong ALK; Lim C; Poon SH; Chua MLK; Chua KLM; Kusumawidjaja G; Chua ET; Wong FY; Lee TS
BMC Cancer; 2020 Oct; 20(1):1045. PubMed ID: 33126867
[TBL] [Abstract][Full Text] [Related]
8. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.
Brown PD; Jaeckle K; Ballman KV; Farace E; Cerhan JH; Anderson SK; Carrero XW; Barker FG; Deming R; Burri SH; Ménard C; Chung C; Stieber VW; Pollock BE; Galanis E; Buckner JC; Asher AL
JAMA; 2016 Jul; 316(4):401-409. PubMed ID: 27458945
[TBL] [Abstract][Full Text] [Related]
9. Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG).
Grosu AL; Frings L; Bentsalo I; Oehlke O; Brenner F; Bilger A; Fennell JT; Rothe T; Schneider-Fuchs S; Graf E; Schmoor C; Beck J; Becker G; Bock M; Egger K; Urbach H; Lahmann C; Popp I
BMC Cancer; 2020 Jun; 20(1):532. PubMed ID: 32513138
[TBL] [Abstract][Full Text] [Related]
10. Automated contouring and planning pipeline for hippocampal-avoidant whole-brain radiotherapy.
Feng CH; Cornell M; Moore KL; Karunamuni R; Seibert TM
Radiat Oncol; 2020 Oct; 15(1):251. PubMed ID: 33126894
[TBL] [Abstract][Full Text] [Related]
11. Hippocampal avoidance with volumetric modulated arc therapy in melanoma brain metastases - the first Australian experience.
Awad R; Fogarty G; Hong A; Kelly P; Ng D; Santos D; Haydu L
Radiat Oncol; 2013 Mar; 8():62. PubMed ID: 23497418
[TBL] [Abstract][Full Text] [Related]
12. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.
Chang EL; Wefel JS; Hess KR; Allen PK; Lang FF; Kornguth DG; Arbuckle RB; Swint JM; Shiu AS; Maor MH; Meyers CA
Lancet Oncol; 2009 Nov; 10(11):1037-44. PubMed ID: 19801201
[TBL] [Abstract][Full Text] [Related]
13. Early experience with hippocampal avoidance whole brain radiation therapy and simultaneous integrated boost for brain metastases.
Lebow ES; Hwang WL; Zieminski S; Wang Y; Niemierko A; Mehan WA; Oh KS; Khandekar M; Willers H; Shih HA
J Neurooncol; 2020 May; 148(1):81-88. PubMed ID: 32307637
[TBL] [Abstract][Full Text] [Related]
14. The impact of RTOG 0614 and RTOG 0933 trials in routine clinical practice: The US Survey of Utilization of Memantine and IMRT planning for hippocampus sparing in patients receiving whole brain radiotherapy for brain metastases.
Slade AN; Stanic S
Contemp Clin Trials; 2016 Mar; 47():74-7. PubMed ID: 26718093
[TBL] [Abstract][Full Text] [Related]
15. Treatment planning strategy for whole-brain radiotherapy with hippocampal sparing and simultaneous integrated boost for multiple brain metastases using intensity-modulated arc therapy.
Pokhrel D; Sood S; McClinton C; Shen X; Lominska C; Saleh H; Badkul R; Jiang H; Mitchell M; Wang F
Med Dosim; 2016 Winter; 41(4):315-322. PubMed ID: 27692518
[TBL] [Abstract][Full Text] [Related]
16. Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy: a prospective study.
Tsai PF; Yang CC; Chuang CC; Huang TY; Wu YM; Pai PC; Tseng CK; Wu TH; Shen YL; Lin SY
Radiat Oncol; 2015 Dec; 10():253. PubMed ID: 26654128
[TBL] [Abstract][Full Text] [Related]
17. Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer.
Zhou L; Liu J; Xue J; Xu Y; Gong Y; Deng L; Wang S; Zhong R; Ding Z; Lu Y
Radiat Oncol; 2014 May; 9():117. PubMed ID: 24884773
[TBL] [Abstract][Full Text] [Related]
18. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.
Brown PD; Ballman KV; Cerhan JH; Anderson SK; Carrero XW; Whitton AC; Greenspoon J; Parney IF; Laack NNI; Ashman JB; Bahary JP; Hadjipanayis CG; Urbanic JJ; Barker FG; Farace E; Khuntia D; Giannini C; Buckner JC; Galanis E; Roberge D
Lancet Oncol; 2017 Aug; 18(8):1049-1060. PubMed ID: 28687377
[TBL] [Abstract][Full Text] [Related]
19. Effect of the simulated half leaf width of a multileaf collimator on volumetric modulated arc therapy plan quality in hippocampal avoidance whole-brain radiotherapy.
Li MH; Chen LJ; Chang CC; Tsai JT; Lin JC
J Appl Clin Med Phys; 2022 May; 23(5):e13575. PubMed ID: 35239259
[TBL] [Abstract][Full Text] [Related]
20. Hippocampus-avoidance whole-brain radiation therapy with a simultaneous integrated boost for multiple brain metastases.
Popp I; Rau S; Hintz M; Schneider J; Bilger A; Fennell JT; Heiland DH; Rothe T; Egger K; Nieder C; Urbach H; Grosu AL
Cancer; 2020 Jun; 126(11):2694-2703. PubMed ID: 32142171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]